Genzyme Corp.

How do you whittle 35 years of headlining business news down to a couple thousand words and a few pages? You don't. But here, we take our best shot to highlight the companies, individuals, and moments that left a lasting impression.

A 25,000-square-foot office building in Framingham that formerly housed the drugmaker Genzyme has sold for $3.2 million.

The Genzyme global operations and distribution center in Northborough has been sold to a Chicago investment company for $20.875 million.

The area's largest biomedical company has expanded its Westborough footprint by nearly 50 percent with a new lease at One Research Drive.

Cambridge-based Genzyme Corp. will move part of its operations in Framingham to Westborough by the end of the year, taking with it 500 employees, the company said.

Cambridge-based Genzyme Corp. will move its corporate offices from Framingham to One Research Drive in Westborough by the end of the year, according to David Ferris of Marlborough-based Ferris Development Group, which owns the property.

Move over, Cambridge. If recent expansions and arrivals are any indication, Framingham might be a new mecca for technology companies. Susan Herzberg, CEO of Boston Heart Diagnostics, said town policies on permitting have changed during her four years with the company, a span in which the company has negotiated a few different leases. Coupled with Framingham's natural attributes, she thinks the more business-friendly approach makes the town a true destination for tech firms.

Genzyme said its multiple sclerosis treatment, Lemtrada, has been recommended for reimbursement in the United Kingdom's health care system.

Genzyme plans to resubmit its application to U.S. regulators for its multiple sclerosis (MS) treatment, the Cambridge-based drug maker said Monday.

Alnylam Pharmaceuticals Inc., a Cambridge company that has allied with Genzyme to develop RNAi therapeutics across the world, has received a positive opinion from European officials on an application for orphan drug status to treat a rare genetic disease that causes fatal organ and nerve damage.